drugset / Trial / NCT00193323

Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients

NCT00193323 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine.

Timeline

Start
2001-08
Primary completion
2006-05
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 30 mg/m2 —
Subject Docetaxel Small molecule 36 mg/m2 —
Subject Gemcitabine Small molecule 800 mg/m2 —

Indications